Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Lilly, a sweet and social 1-year-old old terrier with a lot of positive qualities, is available for adoption at The Cat House ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Detective Cordelia Cupp uncovers the truth through careful investigation and attention to detail, culminating in a shocking ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Bethany Lilly, a Leukemia & Lymphoma Society rep, asked a House panel to remember the sickest patients when considering ...

Lilly Bells was stuck in a tree, 30 feet off the ground, for two whole days. Start the day smarter. Get all the news you need ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Sahara, Safari, Lek, Lilly and Naree are among the rescue dogs working at the site of the building that collapsed in Bangkok ...

Shares of Sangamo Therapeutics Inc (NASDAQ: SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE: LLY ). The deal ...

Laurence Fishburne is revealing why he did not return as Morpheus for “The Matrix Resurrections,” and it turns out, it wasn’t Fishburne’s decision to be excluded from the ...